Drug Design and Discovery Unit 

أنجازات و حدة أكتشاف و تصميم الدواء

Propriety Rights and Patents achieved through the Drug Discovery Unit

Published articles from research projects conducted at the Drug Discovery Unit

Awards gained through research projects conducted at the Drug Discovery Unit

 

 أنجازات و حدة أكتشاف و تصميم الدواء

  1.  أتم 11 طالب ماجستير رسائلهم بالاعتماد الكلي أو الجزئي على حواسيب و برمجيات النمذجة الجزيئية المتوفرة في وحدة اكتشاف و تصميم الدواء.
  2. أتم 4 طلاب دكتوراة رسائلهم بالاعتماد الكلي أو الجزئي على حواسيب و برمجيات النمذجة الجزيئية و المتوفرة في وحدة اكتشاف و تصميم الدواء.
  3. يقوم الآن طالبي  ماجستير و 4 طلاب دكتوراة بإتمام رسائلهم  بالاعتماد الكلي أو الجزئي على حواسيب و برمجيات النمذجة الجزيئية المتوفرة في وحدة اكتشاف و تصميم الدواء.
  4. تم عقد Symposium في الجامعة الأردنية بتاريخ 29/8/2003 لشرح التطورات المختلفة في موضوع النمذجة الجزئية و اكتشاف الأدوية  و ما تم ضمن الجامعة الأردنية في هذا الموضوع. وقد حضر هذا اللقاء جمع غفير من الأكاديميا و الصناعة في الأردن.
  5. تم نشر 22 بحث تتعلق باستعمال تقنيات النمذجة الجزيئية في وحدة اكتشاف و تصميم الأدوية و ذلك في مجلات علمية ذات أثر عالي (High Impact Factor).
  6. ثلاث من  الأوراق العلمية المنشورة و المتعلقة بوحدة اكتشاف و تصميم الدواء قد نالت جوائز البحث المميز في الجامعة الأردنية للعام الأكاديمي 2005 و جائزة جامعة النجاح للبحث المميز للعام 2009 وجائزة وزارة التعليم العالي و البحث العلمي الأردنية للعام 2008
  7. كما أن ثلاث من الأبحاث  قد نشرت في مجلة ( Journal of Medicinal Chemistry)  و التي لها Impact Factor خمس درجات - الأعلى على مستوى العالم في مجال التخصص.

Propriety Rights and Patents achieved through the Drug Discovery Unit

  • Software Copyrights: A 3D Multiconformer Virtual Structure Database of established drugs and agrochemicals. Mutasem O. Taha. 2008.
  • Software Copyrights: Binding Interactions Locator - Docking-based Comparative Intermolecular Contacts Analysis (dbCICA). Khaled Younis and Mutasem O Taha. 2008.
  • Software Copyrights: QSARtool – Acccess to Nonlinear Quantitative Structure-Activity Relationship Analyses.  Khaled Younis and Mutasem O Taha. 2008.
  • Software Copyrights A flexible, digital, three-dimensional structural database suitable for in-silico screening that include 30,000 natural compounds isolated from east-mediteranian flora. Registered within the Jordanian Ministry of Trade and Industry.
  • Pending Patent: Use of phenobarbital for the treatment of wounds. Disi, Ahmad; Ajwee, Dema; Taha, Mutasem; Qunaibi, Eyad.
  • Pending Patent: use of ethosuximide for the treatment of wounds.  Taha, Mutasem; Ajwee, Dema; Disi, Ahmad; Qunaibi, Eyad.

Published articles from research projects conducted at the Drug Discovery Unit

  1. Ligand-Based Assessment of Factor Xa Binding Site Flexibility via Elaborate Pharmacophore Exploration and Genetic Algorithm-Based QSAR Modeling. Taha, Mutasem O.; Qandil, Amjad M.; Zaki, Dhia D.; Murad A. AlDamen. European Journal of Medicinal Chemistry, 2005, 40(7), 701-727. (ISI Impact Factor for 2008 = 2.882)
  2. QSPR Modeling of Pseudoternary Microemulsions Formulated Employing Lecithin Surfactants: Application of Data Mining, Molecular and Statistical Modeling. Mutasem O. Taha, Heba Abdel-Halim, Mutasim Al-Ghazawi, Enam Khalil. International Journal of Pharmaceutics. 2005, 295, 135-155. (ISI Impact Factor for 2008 = 3.061)
  3. Effects of variable docking conditions and scoring functions on the qualities of protein aligned CoMFA models constructed from diverse h-PTP 1B inhibitors. Mutasem O. Taha, Murad AlDhamin. Journal of Medicinal Chemistry. 2005, 48, 8016-8034. (ISI Impact Factor for 2008 = 4.898)
  4. Berberine potently inhibits protein tyrosine phosphatase 1B: investigation by docking simulation and experimental validation. Bustanji, Y.; Taha, M. O.; Yousef, M.; Bakri, AG. Journal of Enzyme Inhibition and Medicinal Chemistry.  2006, 21,163-71. (ISI Impact Factor for 2008 = 1.421)
  5. Discovery of potent inhibitors of pseudomonal quorum sensing via pharmacophore modeling and in silico screening.  Mutasem O. Taha, Amal G. Al-Bakri and Waleed A. Zalloum Bioorganic & Medicinal Chemistry Letters, 2006,16, 5902-5906.  (ISI Impact Factor for 2008 = 2.531
  6. Discovery of New Potent Human Protein Tyrosine Phosphatase Inhibitors Via Pharmacophore and QSAR Analysis Followed by In-Silico Screening. Mutasem O. Taha, Yasser Bustanji, Amal G. Al-Bakri, Al-Motassem Yousef, Waleed A. Zalloum, Ihab M. Al-Masri and Naji Atallah. Journal of Molecular Graphics and Modelling,  2007, 25, 870–884. (ISI Impact Factor for 2008 = 2.347)
  7. Combining Docking, Scoring and Molecular Field Analyses To Probe Influenza Neuraminidase-Ligand Interactions. Areej M. Abu Hammad, Fatima Afifi, Mutasem O. Taha. Journal of Molecular Graphics and Modelling, 2007. 26, 443–456. (ISI Impact Factor for 2008 = 2.347)
  8. Discovery of New MurF Inhibitors via Pharmacophore Modeling and QSAR Analysis followed by in-silico screening. Mutasem O. Taha, Naji Atallah, Amal G. Al-Bakri, Catherine Paradis-Bleau, Hiba Zalloum , Khaled Younis and Roger C. Levesque. Bioorganic and Medicinal Chemistry. 2008, 16, 1218-1235. (ISI Impact Factor for 2008 = 3.075)
  9. Olanzapine inhibits glycogen synthase kinase-3b: an investigation by docking simulation and experimental validation. Mohammad K. Mohammad, Ihab M. Al-Masri, Mutasem O Taha, Mohamed A. S. Al-Ghussein, Hatim S. AlKhatib, Samer Najjar, Yasser Bustanji. European Journal of Pharmacology, 2008, 584, 185–191. (ISI Impact Factor for 2008 = 2.787)
  10.  Pharmacophore Modeling, Quantitative Structure-Activity Relationship Analysis and In Silico Screening Reveal Potent Glycogen Synthase Kinase-3 Inhibitory Activities for Cimetidine, Hydroxychloroquine and Gemifloxacin. Mutasem O. Taha, Yasser Bustanji, Mohamed A.S. Al-Ghussein, Mohammad Mohammad, Hiba Zalloum, Ihab M. Al-Masri, Naji Atallah. Journal of Medicinal Chemistry, 2008, 51, 2062–2077 (ISI Impact Factor for 2008 = 4.898)
  11. Development of Predictive In Silico Model for Cyclosporine- and Aureobasidin-Based P-Glycoprotein Inhibitors Employing Receptor Surface Analysis. Hiba M. Zalloum, Mutasem O. Taha, Journal of molecular graphics and Modelling, 2008, 27, 439–451. (ISI Impact Factor for 2008 = 2.347)
  12. Inhibition of Glycogen Synthase Kinase by Curcumin: Investigation by Simulated Molecular Docking and Subsequent in vitro/in vivo evaluation. Yasser Bustanji, Mutasem O.Taha, Ihab M. Almasri, Mohamed A.S. Al-Ghussein, Mohammad, K. Mohammad,  and Hatim S. AlKhatib, Journal of Enzyme Inhibition and Medicinal Chemistry. 2009, 771 – 778.  (ISI Impact Factor for 2008 = 1.421)
  13. Combining Ligand-Based Pharmacophore Modeling, QSAR Analysis and In -Silico Screening for the Discovery of New Potent Hormone Sensitive Lipase Inhibitors. Mutasem O. Taha, Lina A. Dahabiyeh, Yasser Bustanji, Hiba Zalloum, Suheer Saleh. Journal of Medicinal Chemistry, 2008, 51, 6478–6494.  (ISI Impact Factor for 2008 = 4.898).
  14. Discovery of New DPP IV Inhibitors via Pharmacophore Modeling and QSAR Analysis followed by in-silico screening. Ihab M. Al-Masri, Mohammad K. Mohammad, Mutasem O. Taha. ChemMedChem, 2008, 3, (11), 1763-1779. (ISI Impact Factor for 2008 = 3.150)
  15. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. Ihab M. Al-masri, Mohammad K. Mohammad, Mutasem O. Taha. Journal of Enzyme Inhibition and Medicinal Chemistry. 2009, 24(5), 1061-1066.  (ISI Impact Factor for 2008 = 1.421)
  16. Homology modeling of MCH1 receptor and validation by docking/scoring and protein-aligned CoMFA. Areej Abu-Hammad, Waleed A. Zalloum, Hiba Zalloum, Ghassan Abu-Sheikha, Mutasem O. Taha. European Journal of Medicinal Chemistry, 2009, 44, 2583–2596. (ISI Impact Factor for 2008 = 2.882)
  17. Docking simulations and in vitro assay unveil potent inhibitory action of papaverine against protein tyrosine phosphatase 1B. Yasser Bustanji, Mutasem O. Taha, Ihab Mustafa. Almasri, Mohammad Khalil. Mohammad. Biological and Pharmaceutical Bulletin, 2009, 32 (4), 640-645.  (ISI Impact Factor for 2008 = 1.765)
  18. Pharmacophore modelling, Quantitative Structure-Activity Relationship Analysis and Shape-Complemented In-Silico Screening Allow Access to Novel Influenza Neuraminidase Inhibitors. Areej M. Abu Hammad, Mutasem O. Taha. Journal of Chemical Information and Modeling. 2009, 49, 978–996 (ISI Imapact Factor for 2008 = 3.643)
  19.  Phenytoin Enhances Collagenization in Excision Wounds and Tensile Strength in Incision Wounds. Eyad Qunaibi, Ahmad Disi, Mutasem Taha. Pharmazie, 2009, 64, 584-586. (ISI Impact Factor for 2008 = 0.858)
  20. In Silico Screening for Non-Nucleoside HIV-1 Reverse Transcriptase Using ADMET-filtration and High Throughput Docking. Yasser Bustanji, Mutasem O. Taha, Ihab M. Al-masri. Chemical Biology & Drug Design, 2009; 74: 258–265. (ISI Impact Factor for 2008 = 2.375)
  21. Pharmacophore and QSAR Modeling of Estrogen Receptor B Ligands and Subsequent Validation and In Silico Search for New Hits. Mutasem O. Taha, Mai Tarairah, Hiba Zalloum, Ghassan Abu-Sheikha. Journal of molecular graphics and Modelling, 2010, 28 383–400 (ISI Impact Factor for 2008 = 2.347)
  22. Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration. Reema Abu Khalaf, Ghassan Abu Sheikha, Yasser Bustanji, Mutasem O. Taha. European Journal of Medicinal Chemistry. 2010, In Press (ISI Impact Factor for 2008 = 2.882)

Awards gained through research projects conducted at the Drug Discovery Unit

  • The Jordan University Prize for Distinguished Research Projects in 2005 for the paper entitled: “Ligand-Based Assessment of Factor Xa Binding Site Flexibility via Elaborate Pharmacophore Exploration and Genetic Algorithm-Based QSAR Modeling.” Published in the European Journal of Medicinal Chemistry, 2005, 40(7), 701-727.
  • The Prize of The Jordanian Ministry of Higher Education for Distinguished Research Projects in 2008 for the paper entitled:  "Effects of variable docking conditions and scoring functions on the qualities of protein aligned CoMFA models constructed from diverse h-PTP 1B inhibitors. Mutasem O. Taha*, Murad AlDhamin. Journal of Medicinal Chemistry. 2005, 48, 8016-8034."
  • An-Najah Research Award for the year 2009 for the paper entitled: "Combining Ligand-Based Pharmacophore Modeling, QSAR Analysis and In -Silico Screening for the Discovery of New Potent Hormone Sensitive Lipase Inhibitors. Mutasem O. Taha*, Lina A. Dahabiyeh, Yasser Bustanji, Hiba Zalloum, Suheer Saleh. Journal of Medicinal Chemistry, 2008, 51, 6478–6494."